TNDM241220P44000
- 0.00
- 0.000.00%
Tandem Diabetes Care Newsroom
Leerink Partners Keeps Their Buy Rating on Tandem Diabetes Care (TNDM)
Express News | Tandem Diabetes Care Inc : Leerink Partners Cuts Target Price to $58 From $59
This Insider Has Just Sold Shares In Tandem Diabetes Care
Tandem Diabetes Care Announces Upcoming Conference Presentations
Morgan Stanley Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Maintains Target Price $45
Analysts Have Conflicting Sentiments on These Healthcare Companies: Waters (WAT), Pharvaris (PHVS) and Tandem Diabetes Care (TNDM)
Assessing MedTech Impact From Potential China Tariffs
Barclays Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Raises Target Price to $60
A Quick Look at Today's Ratings for Tandem Diabetes Care(TNDM.US), With a Forecast Between $40 to $75
Here's What Analysts Are Forecasting For Tandem Diabetes Care, Inc. (NASDAQ:TNDM) After Its Third-Quarter Results
Tandem Diabetes Care Is Maintained at Buy by Canaccord Genuity
Baird Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $37
Tandem Diabetes Care Analyst Ratings
A Quick Look at Today's Ratings for Tandem Diabetes Care(TNDM.US), With a Forecast Between $37 to $65
RBC Capital Remains a Buy on Tandem Diabetes Care (TNDM)
Express News | Tandem Diabetes Care Inc : Leerink Partners Cuts Target Price to $59 From $62
Tandem Diabetes Care, Inc. (TNDM) Q3 2024 Earnings Conference Call Transcript Summary
Tandem Diabetes Care, Inc. (TNDM) Q3 2024 Earnings Conference Call Transcript
Tandem Diabetes Care, Inc. (TNDM) Reports Q3 Loss, Tops Revenue Estimates
Tandem Diabetes Care | 10-Q: Q3 2024 Earnings Report